Would you treat or monitor a patient with low HBV DNA levels and high ALT? Here’s my take.
Who are the rare patients with hepatitis B infection who can benefit from peginterferon? Here’s my take.
When should we recommend waiting vs starting treatment in women planning to conceive and those who are already in the early or late stages of pregnancy?
Norah Terrault, MD, MPH, has disclosed that she has received consulting fees from Dynavax Technologies, Gilead Sciences, and Novartis and funds for research support from AbbVie, Bristol-Myers Squibb, Gilead Sciences, and Merck.
How do renal dysfunction, insurance coverage, and long-term safety concerns affect whether we should recommend TAF, TDF, or entecavir to our patients starting HBV therapy?
Patients with low levels of HBV DNA are at greater risk of HCC, particularly those with cirrhosis. Read how I evaluate for causes of low-level viremia and manage patients in this situation.
Use this online tool to compare your management selections for your patients with HBV infection, with expert recommendations from Robert S. Brown, MD, MPH; Natalie Bzowej, MD; Jordan J. Feld, MD, MPH; Norah Terrault, MD, MPH; and Tram T. Tran, MD.
In this activity, Tram T. Tran, MD, presents a series of topical case studies featuring patients with chronic hepatitis B, and discusses how our expert faculty chose to manage them.
In this slideset, Dr. Tram T. Tran, MD, discusses expert approaches to selecting HBV therapy in a series of cases studies involving HBV-infected patients.
Listen as expert faculty review key data and guidance on the latest treatment options for HBV infection.
Download this slideset to review key data and guidance on the latest treatment options for HBV infection.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.